VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Active chronic central serous chorioretinopathy    │ Active chronic central serous chorioretinopathy    │     100 │
│ (cCSC)                                             │ (cCSC)                                             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Foveal subretinal fluid (SRF), on optical          │ Foveal subretinal fluid (SRF), on optical          │     100 │
│ coherence tomography (OCT), at Baseline            │ coherence tomography (OCT), at Baseline            │         │
│ Examination                                        │ Examination                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hyperfluorescent areas on indocyanine green        │ Hyperfluorescent areas on indocyanine green        │     100 │
│ angiography (ICGA)                                 │ angiography (ICGA)                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any previous treatments for active CSC             │ Any previous treatments for active CSC             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Previous prescription of mineralocorticoid         │ Previous prescription of mineralocorticoid         │     100 │
│ receptor antagonists, for cCSC or for other        │ receptor antagonists, for cCSC or for other        │         │
│ diseases                                           │ diseases                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Current treatment with corticosteroids (topical or │ Current treatment with corticosteroids (topical or │     100 │
│ systemic), corticosteroid use within 3 months      │ systemic), corticosteroid use within 3 months      │         │
│ before possible start of trial treatment, or       │ before possible start of trial treatment, or       │         │
│ anticipated start of corticosteroid treatment      │ anticipated start of corticosteroid treatment      │         │
│ within the first 2 years from the start of the     │ within the first 2 years from the start of the     │         │
│ trial period                                       │ trial period                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Evidence of another diagnosis that can explain     │ Evidence of another diagnosis that can explain     │     100 │
│ serous SRF or visual loss                          │ serous SRF or visual loss                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Profound chorioretinal atrophy in central macular  │ Profound chorioretinal atrophy in central macular  │     100 │
│ area on ophthalmoscopy and OCT                     │ area on ophthalmoscopy and OCT                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ No hyperfluorescence on ICGA                       │ No hyperfluorescence on ICGA                       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Intraretinal edema on OCT                          │ Intraretinal edema on OCT                          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (relative) Contraindications for FA or ICGA        │ (relative) Contraindications for FA or ICGA        │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (relative) Contraindications for photodynamic      │ (relative) Contraindications for photodynamic      │     100 │
│ treatment (pregnancy, porphyria, severely          │ treatment (pregnancy, porphyria, severely          │         │
│ disturbed liver function). Pregnancy will not be   │ disturbed liver function). Pregnancy will not be   │         │
│ routinely tested in female patients, but the       │ routinely tested in female patients, but the       │         │
│ possibility of pregnancy will be discussed during  │ possibility of pregnancy will be discussed during  │         │
│ screening                                          │ screening                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ (relative) Known contraindications for initiation  │ (relative) Known contraindications for initiation  │     100 │
│ of eplerenone treatment (hyperkalemia, abnormal    │ of eplerenone treatment (hyperkalemia, abnormal    │         │
│ renal clearance, severe hepatic insufficiency      │ renal clearance, severe hepatic insufficiency      │         │
│ (Child-Pugh C), type 2 diabetes mellitus with      │ (Child-Pugh C), type 2 diabetes mellitus with      │         │
│ microalbuminuria, concomitant use of potassium     │ microalbuminuria, concomitant use of potassium     │         │
│ supplements, potassium-sparing diuretics, strong   │ supplements, potassium-sparing diuretics, strong   │         │
│ CYP3A4 inhibitors, or the combination of an ACE-   │ CYP3A4 inhibitors, or the combination of an ACE-   │         │
│ inhibitor and an angiotensin receptor blocking     │ inhibitor and an angiotensin receptor blocking     │         │
│ agent). Pregnancy will not be routinely tested in  │ agent). Pregnancy will not be routinely tested in  │         │
│ female patients, but the possibility of pregnancy  │ female patients, but the possibility of pregnancy  │         │
│ will be discussed during screening                 │ will be discussed during screening                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Soft drusen in treated eye or fellow eye, signs of │ Soft drusen in treated eye or fellow eye, signs of │     100 │
│ choroidal neovascularization on ophthalmoscopy     │ choroidal neovascularization on ophthalmoscopy     │         │
│ and/or FA/ICGA of the study eye                    │ and/or FA/ICGA of the study eye                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Myopia \> 6D                                       │ Myopia > 6D                                        │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Age of ≥ 18 years of age and able to give written  │ Age of = 18 years of age and able to give written  │      98 │
│ informed consent                                   │ informed consent                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Subjective visual loss \> 6 weeks, interpreted as  │ Subjective visual loss > 6 weeks, interpreted as   │      99 │
│ onset of active disease                            │ onset of active disease                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ≥1 ill-defined hyperfluorescent leakage areas on   │ =1 ill-defined hyperfluorescent leakage areas on   │      99 │
│ fluorescein angiography (FA) with retinal pigment  │ fluorescein angiography (FA) with retinal pigment  │         │
│ epithelial window defect(s) that are compatible    │ epithelial window defect(s) that are compatible    │         │
│ with cCSC                                          │ with cCSC                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Best-corrected visual acuity \< 20/200 (Snellen    │ Best-corrected visual acuity < 20/200 (Snellen     │      99 │
│ equivalent)                                        │ equivalent)                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Visual loss and/or serous detachment on OCT \< 6   │ Visual loss and/or serous detachment on OCT < 6    │      99 │
│ weeks                                              │ weeks                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Continuous and/or progressive visual loss \> 18    │ Continuous and/or progressive visual loss > 18     │      99 │
│ months or serous detachment on OCT \> 18 months    │ months or serous detachment on OCT > 18 months     │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Your personal trial has no unique criteria

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 100
Average Levenshtein Ratio of individual lines: 99.47619047619048
OverAll Ratio: 99.73809523809524
